AI-generated summary
This book chapter discusses the possible therapeutic benefit of photobiomodulation therapy and antiviral photodynamic therapy for COVID-19. The authors report that these light-based approaches have been studied in related pulmonary infections such as influenza, SARS-CoV and MERS, but they found no direct study on SARS-CoV-2. They describe the approaches as potential options that would require more animal and human studies.
- Who or what was studied
- unclear
- Limits stated in the abstract
- The authors state that they found no direct study on SARS-CoV-2, and the work is a discussion chapter that calls for further animal and human studies.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photodynamic therapy, Photobiomodulation, Photon. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.